Are anti-interferon antibodies the cause of failure in: chronic HCV hepatitis treatment?
AUTOR(ES)
Barone, Antonio Alci, Tosta, Rose Aparecida Borges, Tengan, Fátima Mitiko, Marins, José Humberto Caetano, Cavalheiro, Norma de Paula, Cardi, Bruno Andrade
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2004-02
RESUMO
A follow-up study was made of 94 chronic hepatitis C patients at a hepatitis clinic in Brazil, after interferon alpha (IFN-alpha) therapy, to determine the influence of anti-interferon antibodies on treatment outcome. Patients diagnosed as having chronic hepatitis C, confirmed by PCR (HCV RNA) and liver biopsy, were treated with interferon alpha 2a or 2b for at least six months, and were followed up for 24 weeks after termination of treatment in order to assess biochemical, virological and clinical pathology responses. Only 6% of the 94 patients developed anti-IFN antibodies, 70% presented a biochemical response and 23% maintained a sustained virological response. Clinical evaluation revealed that in only 2 patients was there progression of fibrosis; the necro-inflammatory score indicated that 72% maintained the same activity, 12% had worsening necro-inflammatory activity, and the remaining 16% had decreased activity. There was no significant correlation of demographic and laboratory variables with levels of anti-interferon antibodies. Similarly, biochemical and virological responses were not influenced by anti-interferon antibodies. Multivariate analysis by logistic regression revealed that clinical pathological parameters, staging and necro-inflammatory activity did not influence the response to the virus.
Documentos Relacionados
- Microinjection of anti-interferon antibodies into cells does not inhibit the induction of an antiviral state by interferon.
- Neutralization of the Phagocytosis-Enhancing Acitivity of Interferon Preparations by Anti-Interferon Serum
- Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice.
- Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis.
- Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus.